Number of nocturnal awakenings · sleep disturbances in dementia
1 finding from 1 review
Number of participants reporting an adverse event · sleep disturbances in dementia
Trazodone showed no clear difference in reporting ≥ 1 adverse event compared with placebo (low certainty).
1 finding from 1 review
Cognitive function · sleep disturbances in dementia
1 finding from 1 review
Quality of life · sleep disturbances in dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Carer burden, well‐being or quality of life · sleep disturbances in dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total nocturnal sleep time (minutes) · sleep disturbances in dementia
1 finding from 1 review
Consolidated nocturnal sleep time · sleep disturbances in dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with trazodone (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
Paroxetine showed no clear difference in failure to respond at 1‐4 weeks compared with trazodone (moderate certainty).
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
1 finding from 1 review
Failure to remit at endpoint · patients with depression
Paroxetine showed no clear difference in failure to remit at endpoint compared with trazodone (moderate certainty).
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with trazodone (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with trazodone (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with trazodone (moderate certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with trazodone (moderate certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with trazodone (moderate certainty).
1 finding from 1 review